IL310292A - Medicinal myotains - Google Patents

Medicinal myotains

Info

Publication number
IL310292A
IL310292A IL310292A IL31029224A IL310292A IL 310292 A IL310292 A IL 310292A IL 310292 A IL310292 A IL 310292A IL 31029224 A IL31029224 A IL 31029224A IL 310292 A IL310292 A IL 310292A
Authority
IL
Israel
Prior art keywords
mutein
seq
cytokine
residue
amino acid
Prior art date
Application number
IL310292A
Other languages
English (en)
Hebrew (he)
Inventor
Ignacio Moraga Gonzalez
Suman Mitra
Silvia Gaggero
Original Assignee
Univ Dundee
Centre Hospitalier Universitair? De Lille
The Universit? De Lille
Institut National De La Sant? Et De Al Rech M?Dicale Inserm
Ignacio Moraga Gonzalez
Suman Mitra
Silvia Gaggero
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2110547.3A external-priority patent/GB202110547D0/en
Application filed by Univ Dundee, Centre Hospitalier Universitair? De Lille, The Universit? De Lille, Institut National De La Sant? Et De Al Rech M?Dicale Inserm, Ignacio Moraga Gonzalez, Suman Mitra, Silvia Gaggero filed Critical Univ Dundee
Publication of IL310292A publication Critical patent/IL310292A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/60Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/61Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL310292A 2021-07-22 2022-07-21 Medicinal myotains IL310292A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2110547.3A GB202110547D0 (en) 2021-07-22 2021-07-22 Therapeutic muteins
FR2203600 2022-04-19
PCT/EP2022/070548 WO2023001987A2 (en) 2021-07-22 2022-07-21 Therapeutic muteins

Publications (1)

Publication Number Publication Date
IL310292A true IL310292A (en) 2024-03-01

Family

ID=82942857

Family Applications (1)

Application Number Title Priority Date Filing Date
IL310292A IL310292A (en) 2021-07-22 2022-07-21 Medicinal myotains

Country Status (6)

Country Link
US (1) US20240352084A1 (https=)
EP (1) EP4373848A2 (https=)
JP (1) JP2024527629A (https=)
CA (1) CA3226397A1 (https=)
IL (1) IL310292A (https=)
WO (1) WO2023001987A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023249425A1 (ko) * 2022-06-22 2023-12-28 ㈜지아이이노베이션 항-cd73 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
AU2024330564A1 (en) 2023-08-30 2026-04-02 Xilio Development, Inc. Vhh masked cytokines and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569215B2 (en) * 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA3007135A1 (en) 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies
MX2018014950A (es) 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
PE20250933A1 (es) 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
US20180339043A1 (en) 2017-05-26 2018-11-29 Janux Therapeutics, Inc. Modified antibodies
US12202911B2 (en) 2017-10-10 2025-01-21 Numab Therapeutics AG Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
IL275426B2 (en) * 2017-12-19 2025-03-01 Xencor Inc Engineered il-2 fc fusion proteins
WO2019152413A1 (en) 2018-02-02 2019-08-08 Oncoimmune, Inc. Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
US10597453B2 (en) 2018-06-29 2020-03-24 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
US20220002370A1 (en) 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
CN119874917A (zh) 2019-06-07 2025-04-25 阿迪马布有限责任公司 工程化的pH依赖性抗CD3抗体及其产生和使用方法
KR102560876B1 (ko) 2019-06-11 2023-07-28 바이오아트라, 인코퍼레이티드 조건부 활성 항-epcam 항체, 항체 단편, 이들의 면역접합체 및 이의 용도
PH12022550326A1 (en) 2019-08-13 2023-03-13 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells

Also Published As

Publication number Publication date
JP2024527629A (ja) 2024-07-25
CA3226397A1 (en) 2023-01-26
WO2023001987A3 (en) 2023-03-16
EP4373848A2 (en) 2024-05-29
US20240352084A1 (en) 2024-10-24
WO2023001987A2 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
JP7447232B2 (ja) アルブミン結合ドメイン融合タンパク質
Saxton et al. Emerging principles of cytokine pharmacology and therapeutics
JP6941664B2 (ja) 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体
JP6041799B2 (ja) Trailr2特異的多量体足場
JP2022180450A (ja) IL15/IL15Rαヘテロ二量体FC-融合タンパク質
CN113286609B (zh) 多聚体t细胞调节多肽及其使用方法
JP2018515085A (ja) 抗がん融合ポリペプチド
US20240352084A1 (en) Therapeutic muteins
KR20220127867A (ko) 편향된 il2 뮤테인 방법 및 조성물
CN116322785A (zh) 包含il-10的双细胞因子融合蛋白
Bick et al. Targeting γc family cytokines with biologics: current status and future prospects
EP4171609A1 (en) Cytokine conjugates
TW202140562A (zh) 雙特異性結合分子
KR20240057442A (ko) 이중특이성 nk 세포 작용제, 제조 방법 및 응용
CN117999280A (zh) 治疗性突变蛋白
JP2023521174A (ja) インターロイキン1受容体アクセサリータンパク質に特異的なバインダーおよびキメラ抗原受容体
US20250236653A1 (en) Targeted low potency il-12 fc fusion proteins and uses thereof
US20250288666A1 (en) Methods and compositions for use in cell therapy of neoplastic disease
RU2786444C2 (ru) Слитые белки с альбумин-связывающими доменами
Fisher Improving CAR-T Cell Proliferation and Efficacy Using Cytokine Stimulation and Novel Fusion Protein Selection
JP2025535705A (ja) インターロイキン21模倣体
CN121194988A (zh) 白细胞介素-2变体及其应用
TW202248218A (zh) 細胞介素結合物
KR20260032470A (ko) Hpv 백신 요법의 결과로 생성된 t 세포 수용체 및 이를 이용하여 환자를 치료하는 방법
CN120916788A (zh) 靶向淋巴结祖细胞耗竭的t细胞的双功能分子和使用方法